IL161669A0 - Chemokine receptor antagonists and methods of use thereof - Google Patents

Chemokine receptor antagonists and methods of use thereof

Info

Publication number
IL161669A0
IL161669A0 IL16166902A IL16166902A IL161669A0 IL 161669 A0 IL161669 A0 IL 161669A0 IL 16166902 A IL16166902 A IL 16166902A IL 16166902 A IL16166902 A IL 16166902A IL 161669 A0 IL161669 A0 IL 161669A0
Authority
IL
Israel
Prior art keywords
methods
receptor antagonists
chemokine receptor
chemokine
antagonists
Prior art date
Application number
IL16166902A
Other languages
English (en)
Original Assignee
Millennium Pharm Inc
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/989,086 external-priority patent/US20020169155A1/en
Application filed by Millennium Pharm Inc, Kyowa Hakko Kogyo Kk filed Critical Millennium Pharm Inc
Priority claimed from PCT/US2002/036953 external-priority patent/WO2003045942A2/fr
Publication of IL161669A0 publication Critical patent/IL161669A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
IL16166902A 2001-11-21 2002-11-13 Chemokine receptor antagonists and methods of use thereof IL161669A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/989,086 US20020169155A1 (en) 1998-09-04 2001-11-21 Chemokine receptor anagonists and methods of use therefor
PCT/US2002/036953 WO2003045942A2 (fr) 1998-09-04 2002-11-13 Antagonistes des recepteurs de la chimiokine et methodes d'utilisation de ces antagonistes

Publications (1)

Publication Number Publication Date
IL161669A0 true IL161669A0 (en) 2004-09-27

Family

ID=32713949

Family Applications (3)

Application Number Title Priority Date Filing Date
IL16166902A IL161669A0 (en) 2001-11-21 2002-11-13 Chemokine receptor antagonists and methods of use thereof
IL161669A IL161669A (en) 2001-11-21 2004-04-29 Chemokine receptor antagonists and methods of use thereof
IL181191A IL181191A (en) 2001-11-21 2007-02-06 History of pyrolidine, pharmaceutical compounds containing them and their use in the preparation of a drug for the treatment of diseases related to the recruitment, activation or recruitment and activation of abnormal leukocyte

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL161669A IL161669A (en) 2001-11-21 2004-04-29 Chemokine receptor antagonists and methods of use thereof
IL181191A IL181191A (en) 2001-11-21 2007-02-06 History of pyrolidine, pharmaceutical compounds containing them and their use in the preparation of a drug for the treatment of diseases related to the recruitment, activation or recruitment and activation of abnormal leukocyte

Country Status (24)

Country Link
EP (3) EP1688418B1 (fr)
JP (5) JP4889920B2 (fr)
KR (3) KR101001092B1 (fr)
CN (3) CN1585772B (fr)
AR (2) AR037394A1 (fr)
AT (1) ATE320431T1 (fr)
AU (1) AU2002352772B2 (fr)
BR (1) BR0213633A (fr)
CA (1) CA2467672C (fr)
CY (1) CY1107243T1 (fr)
DE (2) DE60209937D1 (fr)
DK (1) DK1448566T5 (fr)
ES (2) ES2396186T3 (fr)
HK (2) HK1063789A1 (fr)
IL (3) IL161669A0 (fr)
MY (2) MY142646A (fr)
NO (1) NO328166B1 (fr)
NZ (3) NZ532827A (fr)
PL (2) PL217918B1 (fr)
PT (1) PT1448566E (fr)
SG (2) SG195393A1 (fr)
SI (1) SI1448566T1 (fr)
TW (1) TWI308568B (fr)
ZA (1) ZA200403530B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002352772B2 (en) * 2001-11-21 2006-10-26 Kyowa Hakko Kogyo Co., Ltd. Chemokine receptor antagonists and methods of use thereof
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
ES2425776T3 (es) * 2007-12-03 2013-10-17 Novartis Ag Derivados 1,2-disustituidos de 4-bencilamino-pirrolidina como inhibidores CETP útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis
PE20091057A1 (es) * 2007-12-19 2009-07-20 Lilly Co Eli Antagonistas del receptor mineralcorticoide y metodos de uso
CN104292142B (zh) * 2013-07-17 2019-05-14 天津大地康和医药技术有限公司 一种n-芳基杂环丁烷脱芳基方法
CN105237455A (zh) * 2015-10-14 2016-01-13 湖南华腾制药有限公司 一种3-取代氮杂环丁烷的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD80449A (fr) *
JPS5250634B2 (fr) 1971-08-23 1977-12-26
JPS61152673A (ja) 1984-12-26 1986-07-11 Kyowa Hakko Kogyo Co Ltd ジベンズ〔ｂ，ｅ〕オキセピン誘導体の製造法
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
JPH0678315B2 (ja) 1988-04-28 1994-10-05 シェリング・コーポレーション 新規なベンゾピリド‐ピペリジン、ピペリジリデンおよびピペラジン化合物、組成物、製造法および利用法
EP0586560A1 (fr) 1991-05-23 1994-03-16 Schering Corporation Nouveaux composes de benzopyrido piperidylidene, compositions, procedes de preparation et d'utilisation
AU2392392A (en) 1991-07-23 1993-02-23 Schering Corporation Novel benzopyrido piperylidene compounds, compositions, methods of manufacture and methods of use
DE69333885T2 (de) 1992-11-10 2006-09-14 Genentech, Inc., South San Francisco C-c ckr-1, ein c-c chemokin rezeptor
AU5270796A (en) * 1995-04-07 1996-10-23 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters th ereof
AU704825B2 (en) * 1995-12-15 1999-05-06 Novo Nordisk A/S Novel method
US6329385B1 (en) * 1998-01-21 2001-12-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6509346B2 (en) * 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2343536A1 (fr) * 1998-09-04 2000-03-16 Yoshisuke Nakasato Antagonistes de recepteur de chemokine et procedes d'utilisation
AU6503900A (en) * 1999-07-28 2001-02-19 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
ATE319775T1 (de) 1999-10-20 2006-03-15 Kingspan Holdings Irl Ltd Zellulärer kunststoff auf basis phenolharz
TW503427B (en) 2000-07-25 2002-09-21 Koninkl Philips Electronics Nv Display tube comprising a mask with vibration damping means
AU2002352772B2 (en) * 2001-11-21 2006-10-26 Kyowa Hakko Kogyo Co., Ltd. Chemokine receptor antagonists and methods of use thereof
DE102011084910A1 (de) 2011-10-20 2013-04-25 Wobben Properties Gmbh Verfahren und Vorrichtung zum Einspeisen elektrischen Stroms in ein elektrisches Netz

Also Published As

Publication number Publication date
PL369599A1 (en) 2005-05-02
CN1585772A (zh) 2005-02-23
EP1688418A2 (fr) 2006-08-09
KR100919346B1 (ko) 2009-09-25
PT1448566E (pt) 2006-08-31
EP1688418B1 (fr) 2017-03-15
KR20100010952A (ko) 2010-02-02
IL181191A0 (en) 2007-07-04
CA2467672A1 (fr) 2003-06-05
ES2260497T3 (es) 2006-11-01
KR20040064283A (ko) 2004-07-16
EP1688418A3 (fr) 2008-05-14
PL403800A1 (pl) 2013-08-19
IL161669A (en) 2010-12-30
JP5936669B2 (ja) 2016-06-22
BR0213633A (pt) 2004-08-24
DE60209937T2 (de) 2006-11-30
KR20070118146A (ko) 2007-12-13
JP2013209393A (ja) 2013-10-10
SG165152A1 (en) 2010-10-28
ES2396186T3 (es) 2013-02-19
DE60209937T4 (de) 2009-10-29
ES2260497T7 (es) 2009-11-05
ZA200403530B (en) 2005-07-28
JP2015083577A (ja) 2015-04-30
MY142646A (en) 2010-12-15
TWI308568B (en) 2009-04-11
SG195393A1 (en) 2013-12-30
NO328166B1 (no) 2009-12-21
JP2005510565A (ja) 2005-04-21
IL181191A (en) 2012-10-31
HK1063789A1 (en) 2005-01-14
NZ596484A (en) 2013-05-31
NO20042500L (no) 2004-06-15
EP2286811B1 (fr) 2012-09-05
JP2016138122A (ja) 2016-08-04
CA2467672C (fr) 2011-06-28
EP1448566A2 (fr) 2004-08-25
KR100952767B1 (ko) 2010-04-14
NZ585746A (en) 2011-12-22
EP1448566B1 (fr) 2006-03-15
JP4889920B2 (ja) 2012-03-07
CN1911930A (zh) 2007-02-14
AR037394A1 (es) 2004-11-10
EP2286811A1 (fr) 2011-02-23
ATE320431T1 (de) 2006-04-15
HK1154504A1 (en) 2012-04-27
MY146601A (en) 2012-08-30
DE60209937D1 (de) 2006-05-11
EP1448566B3 (fr) 2009-04-08
DK1448566T5 (da) 2009-08-03
KR101001092B1 (ko) 2010-12-14
AU2002352772B2 (en) 2006-10-26
CY1107243T1 (el) 2012-11-21
DK1448566T3 (da) 2006-07-31
CN1585772B (zh) 2014-06-04
NZ532827A (en) 2007-09-28
JP2010229136A (ja) 2010-10-14
PL217918B1 (pl) 2014-09-30
AU2002352772A1 (en) 2003-06-10
JP5878494B2 (ja) 2016-03-08
CN104031054A (zh) 2014-09-10
AR090829A2 (es) 2014-12-10
SI1448566T1 (sl) 2006-08-31
TW200303197A (en) 2003-09-01

Similar Documents

Publication Publication Date Title
HK1060727A1 (en) Antagonists of mcp-1 function and methods of use thereof
HK1060728A1 (en) Antagonists of mcp-1 function and methods of use thereof
PL363011A1 (en) Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
EP1541585A4 (fr) Antagoniste de cxcr4 et son utilisation
AU5716901A (en) G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
EP1608318A4 (fr) Antagonistes cxcr4 et leurs procedes d'utilisation
IL161329A0 (en) Benzamide and heteroarylamide as p2x7 receptor antagonists
HK1154504A1 (en) Chemokine receptor antagonists and methods of use thereof
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
IL158701A0 (en) Novel use of nk3 receptor antagonist
EP1536813A4 (fr) Compositions et procedes comprenant des antagonistes des recepteurs actives de proteines
AU2003277215A8 (en) Novel neurokinin antagonists and methods of use thereof
IL198759A (en) Use of 3gal receptor antagonists to prepare medications to treat depression and / or anxiety
AU2003260072A8 (en) Antagonists of chemokine receptors
AU2002351175A8 (en) Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
HUP0401535A3 (en) Somatostatin antagonists and their use
AU3958902A (en) Crf receptor antagonists and methods relating thereto
AU6503900A (en) Chemokine receptor antagonists and methods of use therefor
AU2002363938A8 (en) Methods and use of motoneuronotropic factors
AU6389900A (en) Chemokine receptor antagonists and methods of use therefor
AU2003247052A1 (en) Mcp-1 receptor antagonists and method of use thereof
PL370367A1 (en) Ccr-3 receptor antagonists v
AU2003300396A8 (en) Chemokine antagonists and uses thereof
EP1324763A4 (fr) Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci
EP1539955A4 (fr) Polynucleotides codant pour les recepteurs couples aux proteines g et methodes d'utilisation